<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495935</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#15-478</org_study_id>
    <nct_id>NCT02495935</nct_id>
  </id_info>
  <brief_title>Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia</brief_title>
  <official_title>Feasibility and Efficacy of Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harold P. Koller, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Judith B. Lavrich, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, parallel group sham-controlled blinded clinical trial to&#xD;
      assess the feasibility and efficacy of transcorneal electrical stimulation (TES) in the&#xD;
      improvement of visual function outcomes in adults with amblyopia. The trial will assess the&#xD;
      treatment effect of TES to Sham TES in the amblyopic eye of affected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amblyopia is defined as a decrease in visual acuity in one eye, despite the correction of any&#xD;
      refractive error with glasses and in the absence of any ophthalmoscopically visible lesion of&#xD;
      the retina, especially of the macular region. Amblyopia is associated with histologic and&#xD;
      electrophysiologic abnormalities in the visual pathways.&#xD;
&#xD;
      Transcorneal electrical stimulation (TES), through neural stimulation, works by&#xD;
      non-invasively stimulating the retina via passage of electrical current directly to the&#xD;
      retina, bypassing the usual light activation pathway, resulting in the activation of the same&#xD;
      areas of the brain as would be activated with a light stimulus alone. Electrical stimulation&#xD;
      with TES has shown potential in recent reports as an efficacious treatment modality to&#xD;
      improve visual function.&#xD;
&#xD;
      The success of electrical stimulation in neurodegenerative disorders provides a reasonable&#xD;
      rationale and significant precedent to investigate its potential for use in disorders of the&#xD;
      visual processing system, which functions via an integration of biochemical and electrical&#xD;
      interactions transmitted from the retina.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Best Corrected Visual Acuity (ETDRS letters)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) to Week 16 (4 weeks post last treatment).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amblyopia</condition>
  <arm_group>
    <arm_group_label>OkuStim®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-OkuStim®</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OkuStim®</intervention_name>
    <description>Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany</description>
    <arm_group_label>OkuStim®</arm_group_label>
    <other_name>TES</other_name>
    <other_name>Transcorneal Electrical Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham-OkuStim®</intervention_name>
    <description>Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany</description>
    <arm_group_label>Sham-OkuStim®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Diagnosis of amblyopia made by the principal investigators.&#xD;
&#xD;
          3. Best corrected visual acuity in the amblyopic eye equal to or worse than 20/70&#xD;
&#xD;
          4. Willing and able to give informed consent and to participate for the full duration of&#xD;
             the study.&#xD;
&#xD;
          5. Strabismus less than 10 prism diopters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other significant ophthalmologic disorder or condition with relevant effect upon&#xD;
             visual function as evaluated by principal investigator. (eg. Retinal degeneration,&#xD;
             proliferative diabetic retinopathy, age related macular degeneration, optic nerve&#xD;
             abnormality)&#xD;
&#xD;
          2. Women who are pregnant or women with childbearing potential who are unwilling to use&#xD;
             medically acceptable means of birth control for study duration.&#xD;
&#xD;
          3. Presence of a pacemaker, any metal artifacts in head and trunk, any history of&#xD;
             epileptic seizure or severe psychiatric disease (schizophrenia, etc.)&#xD;
&#xD;
          4. Inability to detect phosphenes above 0.5mA at time of threshold detection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Avrey Thau</last_name>
    <phone>215-928-3418</phone>
    <email>AThau@willseye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelson</last_name>
    <email>LNelson@willseye.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>WillsEye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Dr. Leonard B. Nelson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>TES</keyword>
  <keyword>Transcorneal Electrical Stimulation</keyword>
  <keyword>Amblyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amblyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

